Home
/ AstraZeneca
/ Financials & Metrics

AstraZeneca (AZN.L) stock price, revenue, and financials

AstraZeneca market cap is £162.9 b, and annual revenue was $37.42 b in FY 2021

View Company

£162.9 B

AZN.L Mkt cap, 27-Apr-2022

$37.4 B

AstraZeneca Revenue FY, 2021

AstraZeneca Gross profit (FY, 2021)33 B

AstraZeneca Net income (FY, 2021)115 M

AstraZeneca EBITDA (FY, 2021)7 B

AstraZeneca EBIT (FY, 2021)992 M

AstraZeneca Cash, 31-Dec-20216.3 B

AstraZeneca EV187.3 B

AstraZeneca Revenue Breakdown

Business Segment

Embed Graph

AstraZeneca revenue breakdown by business segment: 34.9% from ONCOLOGY, 6.3% from OTHER MEDICINES, 10.7% from COVID-19, 21.4% from BIOPHARMACEUTICALS: CVRM, 16.1% from BIOPHARMACEUTICALS: R&I, 8.2% from RARE DISEASE and 2.3% from Other

Annual

USD	FY, 2018	FY, 2019	FY, 2020	FY, 2021
Revenue	22.1b	24.4b	26.6b	37.4b
Cost of goods sold	(1.2b)	(1.2b)	(2.2b)	(5.9b)
Gross profit	21.7b	23.7b	25.0b	33.0b
R&D expense	(5.9b)	(6.1b)	(6.0b)	(9.7b)
Operating expense total	(16.4b)	(18.2b)	(17.8b)	(25.9b)
Depreciation and amortization	(3.8b)	(3.8b)	(3.1b)	(6.5b)
EBITDA	5.2b	5.4b	7.2b	7.0b
EBIT	3.3b	2.8b	5.1b	992.0m
Interest expense	(1.4b)	(1.4b)	(1.3b)	(1.3b)
Interest income	138.0m	22.0m	36.0m
Pre tax profit	2.0b	1.5b	3.9b	(265.0m)
Income tax expense	57.0m	(321.0m)	(772.0m)	380.0m
Net Income	2.1b	1.2b	3.1b	115.0m

Quarterly

USD	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021	Q2, 2021	Q3, 2021
Revenue	5.5b	5.8b	6.4b	6.4b	6.3b	6.6b	7.3b	8.2b	9.9b
Cost of goods sold	(453.0m)	(336.0m)	(635.0m)	(579.0m)	(274.0m)	(569.0m)	(1.1b)	(1.4b)	(969.0m)
Gross profit	5.6b	5.6b	6.1b	6.3b	6.1b	6.3b	7.4b	6.9b	8.9b
R&D expense	(1.3b)	(1.4b)	(1.3b)	(1.4b)	(1.4b)	(1.5b)	(1.7b)	(1.8b)	(3.6b)
Operating expense total	(4.4b)	(3.9b)	(4.6b)	(4.6b)	(3.8b)	(4.9b)	(5.1b)	(4.7b)	(8.2b)
Depreciation and amortization	(676.0m)	(727.0m)	(716.0m)	(841.0m)	(710.0m)	(801.0m)	(797.0m)	(753.0m)	(2.8b)
EBITDA	1.2b	1.7b	1.4b	1.7b	2.3b	1.4b	2.4b	2.1b	736.0m
EBIT	1.1b	461.0m	725.0m	1.2b	1.3b	1.2b	1.9b	1.1b	(1.7b)
Interest expense	(367.0m)	(361.0m)	(353.0m)	(332.0m)	(329.0m)	(324.0m)	(303.0m)	(326.0m)	(335.0m)
Interest income	55.0m	41.0m	37.0m	51.0m	22.0m	7.0m	20.0m	7.0m	15.0m
Pre tax profit	758.0m	141.0m	409.0m	935.0m	961.0m	853.0m	1.6b	764.0m	(2.0b)
Income tax expense	(195.0m)	(34.0m)	(129.0m)	(185.0m)	(223.0m)	(202.0m)	(46.0m)	(214.0m)	350.0m
Net Income	563.0m	107.0m	280.0m	750.0m	738.0m	651.0m	1.6b	550.0m	(1.7b)

Annual

USD	FY, 2018	FY, 2019	FY, 2020	FY, 2021
Cash	4.8b	5.4b	7.8b	6.3b
Accounts Receivable	3.0b	3.6b	3.8b	9.6b
Prepaid Expenses	1.6b	1.2b	2.1b	663.0m
Inventories	2.9b	3.2b	4.0b	9.0b
Current Assets	15.6b	15.6b	19.5b	26.2b
PP&E	7.4b	8.3b	8.3b	9.2b
Goodwill	11.7b	11.7b	11.8b	20.0b
Total Assets	60.7b	61.4b	66.7b	105.4b
Accounts Payable	1.7b	1.8b	2.4b	18.9b
Short-term debt	1.8b	2.0b	2.3b	1.9b
Current Liabilities	16.3b	18.1b	20.3b	22.6b
Long-term debt	17.4b	16.2b	18.0b	28.9b
Non-Current Liabilities	30.3b	28.7b	30.8b	43.5b
Total Debt	19.1b	18.2b	20.3b	30.8b
Total Liabilities	46.6b	46.8b	51.1b	66.1b
Common Stock	317.0m	328.0m	328.0m	387.0m
Additional Paid-in Capital	4.4b	7.9b	8.0b	35.1b
Retained Earnings	5.7b	2.8b	5.3b	1.7b
Total Equity	14.0b	14.6b	15.6b	39.3b

Quarterly

USD	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021	Q2, 2021	Q3, 2021
Cash	4.1b	5.4b	4.0b	3.4b	5.7b	8.1b	7.6b	15.6b	7.1b
Accounts Receivable	5.3b	5.3b	5.3b	5.1b	5.0b	5.7b	6.3b	6.4b	8.3b
Prepaid Expenses	118.0m	246.0m	228.0m	262.0m	213.0m	332.0m	347.0m	486.0m	596.0m
Inventories	3.1b	3.2b	3.1b	3.1b	3.6b	3.7b	4.3b	4.8b	10.5b
Current Assets	13.6b	15.2b	13.5b	12.8b	14.9b	18.2b	18.7b	27.3b	26.7b
PP&E	7.4b	7.4b	8.0b	7.3b	7.5b	7.7b	8.2b	8.4b	9.2b
Goodwill	11.7b	11.7b	11.6b	11.6b	11.6b	11.7b	11.8b	11.8b	20.1b
Total Assets	61.1b	61.9b	58.9b	57.2b	59.9b	64.1b	64.9b	73.6b	107.2b
Accounts Payable	13.1b	12.6b	12.5b	12.6b	12.0b	13.4b	17.4b	17.7b	18.7b
Short-term debt	3.7b	1.8b	577.0m	2.5b	4.1b	3.6b	2.3b	2.9b	3.0b
Current Liabilities	18.3b	16.0b	14.8b	17.0b	18.2b	18.9b	21.5b	22.2b	23.6b
Long-term debt	17.9b	17.9b	17.6b	16.1b	15.6b	18.8b	17.9b	24.6b	28.9b
Non-Current Liabilities	30.8b	30.8b	30.5b	28.0b	28.1b	31.6b	29.0b	35.7b	43.7b
Total Debt	21.6b	19.7b	18.2b	18.6b	19.7b	22.3b	20.1b	27.5b	31.9b
Total Liabilities	49.0b	46.8b	45.2b	45.0b	46.3b	50.5b	50.5b	57.9b	67.3b
Common Stock	317.0m	328.0m	328.0m	328.0m	328.0m	328.0m	328.0m	328.0m	387.0m
Additional Paid-in Capital	4.4b	7.9b	7.9b	7.9b	8.0b	8.0b	8.0b	8.0b	35.1b
Retained Earnings	3.7b	3.3b	1.9b	448.0m	1.9b	1.9b	4.1b	5.3b	2.2b
Total Equity	12.0b	15.1b	13.7b	12.2b	13.7b	13.6b	14.4b	15.7b	39.9b

Annual

USD	FY, 2018	FY, 2019	FY, 2020	FY, 2021
Net Income	2.0b	1.5b	3.9b	(265.0m)
Depreciation and Amortization	3.8b	3.8b	3.1b	6.5b
Accounts Receivable	(523.0m)	(898.0m)	(739.0m)
Inventories	(13.0m)	(316.0m)	(621.0m)
Accounts Payable	(103.0m)	868.0m	1.7b
Cash From Operating Activities	2.6b	3.0b	4.8b	6.0b
Cash From Investing Activities	963.0m	(657.0m)	(285.0m)	(11.1b)
Short-term Borrowings	(98.0m)	(516.0m)	288.0m	(516.0m)
Long-term Borrowings	1.6b	(1.0b)	1.4b	8.2b
Dividends Paid	(3.5b)	(3.6b)	(3.6b)	(3.9b)
Cash From Financing Activities	(2.0b)	(1.8b)	(2.2b)	3.6b
Net Change in Cash	1.5b	552.0m	2.3b	(1.5b)

Quarterly

USD	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021	Q2, 2021	Q3, 2021
Net Income	758.0m	899.0m	1.3b	935.0m	1.9b	2.7b	1.6b	2.4b	371.0m
Depreciation and Amortization	676.0m	1.4b	2.1b	841.0m	1.6b	2.4b	797.0m	1.6b	4.3b
Cash From Operating Activities	(387.0m)	491.0m	1.6b	139.0m	1.2b	3.0b	1.9b	2.8b	4.5b
Cash From Investing Activities	328.0m	(789.0m)	(715.0m)	9.0m	157.0m	(423.0m)	555.0m	319.0m	(10.1b)
Short-term Borrowings	1.2b	(148.0m)	(686.0m)	123.0m	1.4b	858.0m	(240.0m)	(182.0m)	(261.0m)
Long-term Borrowings	500.0m		(1.0b)			3.0b	(4.0m)	7.3b	9.0b
Dividends Paid	(2.4b)	(2.4b)	(3.6b)	(2.4b)	(2.5b)	(3.7b)	(2.5b)	(2.5b)	(3.9b)
Cash From Financing Activities	(698.0m)	941.0m	(1.8b)	(2.4b)	(1.2b)	7.0m	(2.7b)	4.6b	4.7b
Net Change in Cash	(745.0m)	659.0m	(892.0m)	(2.2b)	82.0m	2.6b	(309.0m)	7.7b	(973.0m)

USD	FY, 2018
EV/EBITDA	21.5 x
EV/EBIT	33.8 x
EV/CFO	42.2 x
Revenue/Employee	342.0k

	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q4, 2018	FY, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q4, 2019	FY, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q4, 2020	FY, 2020
Projects in R&D Pipeline	99	133	146	132	144					149					167					171
Phase I Trials Projects	33	24	44	41	50					38					34					35
Phase II Trials Projects	27	11	33	36	37					43					50					42
Phase III Trials Projects	19	11	35	27	23					22					27					25
Life-cycle Management Projects					34					46					56					69
Blood Pressure Screenings (Africa)					5.7 m					9.97 m					13.5 m					16.7 m
New Phase I Projects						5	3	4	3		1	1	1	5	5	3		3	5	5
New Phase II Projects						2		3	4		12	1	4	5	5	1	4	3	8	8
New Pivotal Study Projects						2	1	5	6		6	6	3	1			5	6	8	8
New Projects to Registration						3	1	3			1		5	5			1	3	2	2
NME Phase I (Oncology)					21	19	18	17	26	26	21	21	20	18	18	20	19	20	21	21
NME Phase II (Oncology)					3	4	10	10	20	20	25	22	25	27	27	25	24	25	21	21
NME in Late-stage Development (Oncology)					5	4	4	4	11	11	14	17	14	12	12	7	9	10	10	10
NME Phase I (Biopharmaceuticals)					13	12	12	13	13	13	13	13	14	16	16	17	16	17	14	14
NME Phase II (Biopharmaceuticals)					18	17	17	17	23	23	22	22	21	22	22	20	21	21	21	21
NME in Late-stage Development (Biopharmaceuticals)					4	4	3	2	3	3	3	3	5	5	5	4	6	5	5	5
Healthcare Workers Trained					10.82 k					35.89 k					81.61 k					132.25 k
People Reached (Healthcare Programmes)					7.17 m					12.01 m					16.42 m					25.03 m
People Reached (Patient Assistance Programmes)					9 m					9.3 m					9.7 m					10.1 m
NME Phase I					34					26					32					27
NME Phase II					20					25					39					36
NME in Late-stage Development					11					8					8					10
Countries					100					100					100					100
Health Facilities Activated					827					2 k					2.62 k					3.36 k
Patients Included in Clinical Trials					33 k
Scientific Collaborations					600					630					730					800
Young Health Programme Members					2.25 m					3.01 m					4.01 m

Gender

	FY, 2019	FY, 2018	FY, 2017
Male, percent	10%	10%	10%
Male (Senior and Middle Management), percent	10.9%	11.1%	11.1%
Female (Senior and Middle Management), percent	9.1%	8.9%	8.9%
Female (Management), percent	8.3%	8.3%	8.1%
Female (Executive Leadership), percent	6.4%	6%	5.6%
Male (Executive Leadership), percent	13.6%	14%	14.4%
Female (Board), percent	6.7%	8.4%	8.4%
Male (Board), percent	13.3%	11.6%	11.6%
Male (Management), percent	11.7%	11.7%	11.9%
Female, percent	10%	10%	10%